{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-22-000141","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.337448+00:00","generated_at":"2026-06-22T03:10:53.403205+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Emergent BioSolutions Q3 revenues down 27% to $240M; net loss widens to $75.7M; guidance slashed","bullets":["Total revenues $240M (-27% YoY); net loss $75.7M (-$1.52 EPS) vs loss $32.7M (-$0.61) prior year.","Segment: Products revenue $186.2M (-31%); Services CDMO $36.4M (-13%); nasal naloxone -34%, ACAM2000 -39%, anthrax vaccines +55%.","Completed TEMBEXA acquisition from Chimerix; BARDA contract up to $680M for 1.7M doses over 10 years.","FY2022 guidance revised down: total rev $1.05-1.1B (from $1.15-1.25B); adj EBITDA $0-30M (from $80-120M); ACAM2000 cut to $63M.","Gross margin improved to 33% from 30%; adjusted gross margin 34% from 31%; attributed to mix shift."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-22-000141","json":"https://secwatch.observer/filing/0001367644-22-000141.json","markdown":"https://secwatch.observer/filing/0001367644-22-000141.md","text":"https://secwatch.observer/filing/0001367644-22-000141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000141/0001367644-22-000141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000141/ebs-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:10:53.403205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b54474d4e89602a56aea8f34c16f615a644811c","claim":"Emergent BioSolutions Inc. reported the third quarter ended September 30, 2022 results: revenue Total Revenues $240.0, net income Net Loss $(75.7), EPS Net Loss per Diluted Share $(1.52).","evidence_excerpt":"to deliver results for our patients, customers, and shareholders.” FINANCIAL HIGHLIGHTS (1) ($ in millions, except per share amounts) Q3 2022 Q3 2021 % Change Total Revenues $240.0 $329.0 (27)% Net Loss $(75.7) $(32.7) * Net Loss per Diluted Share $(1.52) $(0.61) * Adjusted Net Loss (2) $(63.2) $(19.3) * Adjusted Net Loss (2) per Diluted Share $(1.27)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000141/0001367644-22-000141-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"Total Revenues $240.0"},{"label":"Net income","value":"Net Loss $(75.7)"},{"label":"EPS","value":"Net Loss per Diluted Share $(1.52)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}